TCGA-CQ-A4CD-01A-21R-A24Z-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- MYC_TARGETS_V2+0.520
- INTERFERON_GAMMA_RESPONSE+0.490
- TNFA_SIGNALING_VIA_NFKB+0.380
- INFLAMMATORY_RESPONSE+0.310
- MYC_TARGETS_V1+0.300
- ANGIOGENESIS+0.290
- COAGULATION+0.260
- E2F_TARGETS+0.250
- ALLOGRAFT_REJECTION+0.240
Top 10 suppressed
- PROTEIN_SECRETION-0.400
- MYOGENESIS-0.300
- CHOLESTEROL_HOMEOSTASIS-0.280
- ANDROGEN_RESPONSE-0.270
- UV_RESPONSE_DN-0.270
- BILE_ACID_METABOLISM-0.260
- MTORC1_SIGNALING-0.220
- HEME_METABOLISM-0.210
- KRAS_SIGNALING_DN-0.210
- PEROXISOME-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-UF-A7JT-01A-11R-A34R-07 | — | — | 0.761 |
| 2 | MNG921 | — | — | 0.759 |
| 3 | BS_GAGRGSSX | ATRT | — | 0.750 |
| 4 | TCGA-66-2782-01A-01R-0851-07 | — | cohortSQ1 | 0.748 |
| 5 | 301853fd-348d-4a99-9625-7da725023c1d | — | — | 0.745 |
| 6 | R61 | — | — | 0.741 |
| 7 | TCGA-GU-A766-01A-11R-A32O-07 | — | — | 0.740 |
| 8 | 22C1A41D-014D-4EFB-AF5B-EFC3FEC1E936 | — | — | 0.732 |
| 9 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.731 |
| 10 | TCGA-PL-A8LZ-01A-31R-A36F-07 | — | D | 0.728 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |